Journal Article > Short ReportFull Text
Lancet Global Health. 1 July 2024; Volume 12 (Issue 7); e1184-e1191.; DOI:10.1016/S2214-109X(24)00148-7
Broger T, Marx FM, Theron G, Marais BJ, Nicol MP, et al.
Lancet Global Health. 1 July 2024; Volume 12 (Issue 7); e1184-e1191.; DOI:10.1016/S2214-109X(24)00148-7
Journal Article > CommentaryFull Text
Lancet Microbe. 31 July 2023; Volume S2666-5247 (Issue 23); 00217-3.; DOI:10.1016/S2666-5247(23)00217-3
Branigan D, Denkinger CM, Furin J, Heitkamp P, Deborggraeve S, et al.
Lancet Microbe. 31 July 2023; Volume S2666-5247 (Issue 23); 00217-3.; DOI:10.1016/S2666-5247(23)00217-3
Journal Article > CommentarySubscription Only
Nat Med. 1 January 2023; Volume 29 (Issue 1); 16-17.; DOI:10.1038/s41591-022-02136-z
McKenna L, Frick M, Angami K, Dubula V, Furin J, et al.
Nat Med. 1 January 2023; Volume 29 (Issue 1); 16-17.; DOI:10.1038/s41591-022-02136-z
Journal Article > ResearchFull Text
PLOS Med. 28 August 2012; Volume 9 (Issue 8); DOI:10.1371/journal.pmed.1001300
Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bayona J, et al.
PLOS Med. 28 August 2012; Volume 9 (Issue 8); DOI:10.1371/journal.pmed.1001300
Treatment of multidrug resistant tuberculosis (MDR-TB) is lengthy, toxic, expensive, and has generally poor outcomes. We undertook an individual patient data meta-analysis to assess the impact on outcomes of the type, number, and duration of drugs used to treat MDR-TB.
Journal Article > Short ReportFull Text
J Infect Dis. 1 April 2015; Volume 211 (Issue suppl_2); DOI:10.1093/infdis/jiu821
Denkinger CM, Kik S, Cirillo DM, Casenghi M, Shinnick T, et al.
J Infect Dis. 1 April 2015; Volume 211 (Issue suppl_2); DOI:10.1093/infdis/jiu821
To accelerate the fight against tuberculosis, major diagnostic challenges need to be addressed urgently. Post-2015 targets are unlikely to be met without the use of novel diagnostics that are more accurate and can be used closer to where patients first seek care in affordable diagnostic algorithms. This article describes the efforts by the stakeholder community that led to the identification of the high-priority diagnostic needs in tuberculosis. Subsequently target product profiles for the high-priority diagnostic needs were developed and reviewed in a World Health Organization (WHO)-led consensus meeting. The high-priority diagnostic needs included (1) a sputum-based replacement test for smear-microscopy; (2) a non-sputum-based biomarker test for all forms of tuberculosis, ideally suitable for use at levels below microscopy centers; (3) a simple, low cost triage test for use by first-contact care providers as a rule-out test, ideally suitable for use by community health workers; and (4) a rapid drug susceptibility test for use at the microscopy center level. The developed target product profiles, along with complimentary work presented in this supplement, will help to facilitate the interaction between the tuberculosis community and the diagnostics industry with the goal to lead the way toward the post-2015 global tuberculosis targets.